Lymphoma: Clinical Trials

147 trials for Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

63 completed, 46 unknown, 16 recruiting, 7 terminated. 147 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4147Completed 63, Unknown 46, Recruiting 16, Terminated 7, Not yet recruiting 6, Active not recruiting 5, Withdrawn 4

Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma

Trials (filtered) newest first · largest first

All 147 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound
Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide - Preeclampsia, Preeclampsia Postpartum
Phase 4RecruitingUniversity of California, Irvine962026-10-262026-11-02
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma
Phase 4RecruitingThe First Hospital of Jilin University262026-10-152026-11-02
Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response
Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 4Not yet recruitingThe First Hospital of Jilin University272026-09-012026-08-12
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer
Phase 4RecruitingDana-Farber Cancer Institute802026-04-232026-08-11
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
ZSDT regimen - Mantle Cell Lymphoma (MCL)
Phase 4Not yet recruitingZhengzhou University302025-12-312025-12-04
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Orelabrutinib - Marginal Zone Lymphoma(MZL)
Phase 4RecruitingBeijing Tongren Hospital882025-11-252026-01-21
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Rituximab, Zanubrutinib - Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
Phase 4RecruitingThe First Affiliated Hospital of Soochow University402025-11-012025-12-08
Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
chidamide+PD-1 inhibitor - Large B-Cell Lymphoma (LBCL), Lymphoma, Large B-Cell, Diffuse
Phase 4RecruitingShanghai Tongji Hospital, Tongji University School of Medicine202025-10-302026-11-13
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia
Phase 4RecruitingGadjah Mada University1202025-06-012025-08-22
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Glofitamab treatment - B Cell Lymphoma (BCL)
Phase 4Not yet recruitingZhengzhou University402025-05-302025-05-02
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Phase 4RecruitingEli Lilly and Company2792025-05-202026-03-02
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Phase 4RecruitingEli Lilly and Company7872025-05-202026-03-02
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
Early receiving G-CSF group, Late receiving G-CSF group - Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor
Phase 4Not yet recruitingDepartment of Medical Services Ministry of Public Health of Thailand1262025-02-012025-01-28
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
Brentuximab Vedotin (Bv), Sintilimab, Tislelizumab - Hodgkin Lymphoma (Category)
Phase 4Not yet recruitingXiuhua Sun1002024-12-312025-01-07
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
Efanesoctocog alfa - Haemophilia A (Moderate or Severe), Hemophilia, Classic
Phase 4Active not recruitingSwedish Orphan Biovitrum372024-12-192026-04-30
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Axicabtagene Ciloleucel - Lymphoma, B-Cell
Phase 4RecruitingZhengzhou University202024-09-302024-10-15
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Brentuximab Vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma
Phase 4RecruitingTakeda1242024-08-282026-02-23
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Pentaisomaltose - Malignant Lymphoma, Multiple Myeloma
Phase 4UnknownPharmacosmos A/S1502024-04-302024-04-03
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
PCV20 - Lymphoma
Phase 4Active not recruitingM.D. Anderson Cancer Center302023-10-062026-09-15
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Relmacabtagene Autoleucel Injection - Relapsed or Refractory B-cell Lymphoma
Phase 4Not yet recruitingChanghai Hospital132023-06-202023-06-15

Showing 20 of 147. Sign in to see all of them.

Narrower conditions

Lymphoma, Follicular (31)  ·  Lymphoma, Non-Hodgkin (30)  ·  Lymphoma, Large B-Cell, Diffuse (14)  ·  Lymphoma, B-Cell (10)  ·  Recurrence (10)  ·  Hodgkin Disease (8)  ·  Lymphoma, T-Cell, Cutaneous (8)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (8)  ·  Leukemia (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (6)  ·  Lymphoma, Mantle-Cell (6)  ·  Mycosis Fungoides (6)  ·  Burkitt Lymphoma (5)  ·  Lymphoma, Extranodal NK-T-Cell (5)

Broader conditions

Neoplasms by Histologic Type (146)  ·  Neoplasms (145)  ·  Hemic and Lymphatic Diseases (143)  ·  Lymphatic Diseases (142)  ·  Immune System Diseases (141)  ·  Immunoproliferative Disorders (141)  ·  Lymphoproliferative Disorders (141)  ·  Lymphoma, Non-Hodgkin (82)  ·  Hematologic Diseases (28)  ·  Pathological Conditions, Signs and Symptoms (25)  ·  Lymphoma, T-Cell (24)  ·  Lymphoma, B-Cell (18)  ·  Pathologic Processes (16)  ·  Disease Attributes (15)

Interventions

Rituximab (13)  ·  Cyclophosphamide (12)  ·  Doxorubicin (9)  ·  Dexamethasone (8)  ·  Etoposide (8)  ·  Vincristine (7)  ·  Granulocyte Colony-Stimulating Factor (6)  ·  Prednisone (6)  ·  Brentuximab Vedotin (5)  ·  Cytarabine (5)  ·  Ifosfamide (5)  ·  Methotrexate (5)  ·  pegylated granulocyte colony-stimulating factor (5)  ·  Aprepitant (4)  ·  Cisplatin (4)

Sponsors

Mingzhi Zhang (9)  ·  Peking University (7)  ·  Zhengzhou University (6)  ·  Ruijin Hospital (5)  ·  Eisai Inc. (4)  ·  Shandong Provincial Hospital (4)  ·  GlaxoSmithKline (3)  ·  Takeda (3)  ·  Biogen (2)  ·  Children's Hospital of Michigan (2)  ·  Chongqing University Cancer Hospital (2)  ·  Depomed (2)  ·  Eli Lilly and Company (2)  ·  Hoffmann-La Roche (2)  ·  Jun Zhu (2)

Countries

China (52)  ·  United States (34)  ·  Germany (12)  ·  Italy (12)  ·  Spain (11)  ·  France (10)  ·  Poland (9)  ·  United Kingdom (9)  ·  Australia (8)  ·  Russia (8)  ·  Sweden (7)  ·  Czechia (6)  ·  South Korea (6)  ·  Taiwan (5)  ·  Turkey (Türkiye) (5)

Top investigators

Jun Zhu (3)  ·  Jun Zhu, MD (3)  ·  Mingzhi Zhang, Pro,Dr (3)  ·  Elyane Lombardy, M.D. (2)  ·  A. Paz Coll, MD (1)  ·  A. Salar, MD (1)  ·  Adrian U Wiestner, M.D. (1)

Results publications

PMID 32632956, PMID 23770157, PMID 11863096, PMID 14585365, PMID 14752084, PMID 15014526, PMID 15158091, PMID 15257960, PMID 15770833, PMID 16648042, PMID 17410187, PMID 18165618, PMID 18626005, PMID 19167677, PMID 19219604, PMID 20118030, PMID 20660832, PMID 21575927, PMID 21828124, PMID 21890336, PMID 21940824, PMID 22198540, PMID 22677206, PMID 23275102, PMID 23317527, PMID 23383989, PMID 23615461, PMID 23753028, PMID 23775967, PMID 23775972, PMID 23938061, PMID 24824768, PMID 25253770, PMID 25311218, PMID 25359988, PMID 25559471, PMID 25934708, PMID 26001791, PMID 26230956, PMID 26808342, PMID 27060152, PMID 27384676, PMID 27686365, PMID 27852260, PMID 28597542, PMID 28664750, PMID 29155058, PMID 29437609, PMID 29610030, PMID 29654631

NIH funding

2009 (2), 2016 (1), 2019 (1), P01CA128115 (1)